Renal Diseases Market Reports Empesis on Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease

The Frontier Pharma: Renal Diseases High Degree of Innovation and Diversity with Products Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease assesses first-in-class innovation in the renal diseases pipeline, highlighting key trends and emerging treatment classes.

Pune, India - March 14, 2018 /MarketersMedia/ —

The renal diseases therapy area encompasses a range of diseases of the kidney, such as chronic kidney disease (CKD), acute kidney injury, diabetic nephropathy and focal segmental glomerulosclerosis. Renal diseases are becoming increasingly common due to the increased prevalence of hypertension and diabetes, two major causes of CKD. For most forms of renal diseases, early detection and management may slow down or prevent progression to renal failure and associated complications. However, many renal diseases are typically asymptomatic until they have progressed to end-stage renal disease (ESRD), which requires renal replacement therapies such as hemodialysis and renal transplantation, and is associated with substantial morbidity and mortality.

Access Report Details at:

The first-in-class programs identified show considerable diversity, and the relatively high degree of innovation in the renal diseases therapy area makes for a promising development pipeline. It is clear that recent activity in this area has increased, partly owing to the growing recognition of the unmet medical need. Further investment in innovation would benefit the therapy area greatly, and likely prove a worthwhile investment, particularly for highly prevalent diseases such as CKD and diabetic nephropathy, for which there are a lack of effective pharmacotherapeutic options.

Get this report at:

• With 365 products in active development, the pipeline is modestly sized. Does current pipeline innovation hold the potential to affect the future renal diseases market?
• There are 100 first-in-class products in the renal diseases pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
• The majority of first-in-class products were in development for indications involving inflammation. Which first-in-class targets are most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
• A significant number of first-in-class products have been identified with no prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Inquire for more details at:

Contact Info:
Name: Shirish Gupta
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL:

For more information, please visit

Source: MarketersMedia

Release ID: 314328

Latest News

China propaganda kicks into overdrive as 'helmsman' Xi re-anointed president

Mar 18, 2018

By Ben BlanchardBEIJING (Reuters) - With pictures of ecstatic citizens standing in applause, happily tearful legislators and even a social media game, China's propaganda drive has kicked into high gear following Xi Jinping's unanimous reappointment as president.Xi's face dominated the front pages of major Sunday newspapers, many carrying the same editorial from the ruling Communist Party's official People's Daily using language once more associated with Mao Zedong to say he was a "leader loved and respected by the people" and "helmsman of the country"."The voyage of a great country cannot do without a helmsman," the paper wrote.The military's official People's...

China plans tougher goals, beefed-up inspections in war on smog

Mar 18, 2018

BEIJING (Reuters) - China will set more stringent targets for improving the nation's air quality under a new three-year plan, as Beijing prepares to beef up a nationwide crackdown on polluters in its years-long campaign to clear its notoriously toxic skies.The new targets for concentrations of small, breathable particles known as PM2.5 will be lower than those in the country's current five-year plan that was due to end in 2020, environment minister Li Ganjie said at a briefing on the sidelines of the country's annual Parliament on Saturday.In January, the Ministry of Environmental Protection (MEP) said it was drawing up...'s finance unit aims to raise $1.9 billion, valuation set to double: sources

Mar 18, 2018

By Julie ZhuHONG KONG (Reuters) - Inc's finance arm is looking to raise about 12 billion yuan ($1.9 billion) in fresh equity that could see its value double from last year to more than $20 billion, three people with knowledge of the matter said.The unit of China's second-largest e-commerce firm is seeking to deepen its push into areas such as securities, banking and insurance - businesses that have seen the entry of several new technology-focused players.The move adds to a flurry of fundraising by Chinese tech firms keen to respond to burgeoning demand for digital services, especially in the...

Chamber of Commerce warns Trump against China tariffs

Mar 18, 2018

WASHINGTON (Reuters) - The head of the most influential U.S. business lobbying group warned the Trump administration that unilateral tariffs on Chinese goods could lead to a destructive trade war that will hurt American consumers and U.S. economic growth.U.S. Chamber of Commerce President Thomas Donohue said in a statement on Thursday that such tariffs, associated with a probe of China's intellectual property practices, would be "damaging taxes on American consumers."His comments came after White House trade adviser Peter Navarro said that Trump would in coming weeks get options to address China's "theft and forced transfer" of American intellectual property as...

Leshi shares plunge after 'white knight' chairman resigns

Mar 18, 2018

By Sijia JiangHONG KONG (Reuters) - Shares in Leshi Internet Information & Technology Corp Beijing slumped 10 percent on Friday after its chairman resigned, fanning fears he would no longer play a white knight role for the embattled firm.Sun Hongbin took on the job only eight months ago after a $2.2 billion investment by his property firm Sunac China Holdings, and had been seen as the main backer for the crumbling LeEco conglomerate, of which Leshi has been the main listed vehicle.But financial woes at LeEco, which once aspired to be both China's Netflix and Tesla, have only deepened with...

Sign up now!